| May 30 |
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
|
| May 29 |
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
|
| May 23 |
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
|
| May 23 |
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
|
